



C9C

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s)	Levi, et al.	Examiner:	Raymond J. Henley III
Serial No.:	10/076,204	Group Art Unit:	1614
Confirmation No:	8595	Docket:	955-16
Filed:	February 13, 2002	Dated:	May 13, 2005
Patent No.:	6,884,809 B2	Issue Date:	April 26, 2005
For:	Method and Compositions for Reducing Cardiac Dysfunctions with a Selective Histamine H <sub>3</sub> Receptor Agonist		

**Certificate**

**MAY 23 2005**

**of Correction**

I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope addressed to Commissioner for  
Patents, PO Box 1450, Alexandria, VA 22313-1450

on May 13, 2005 Signature

*Julie A. Watts*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION OF  
PATENT PURSUANT TO 37 C.F.R. §1.322**

Sir:

Please issue a Certificate of Correction in accordance with 37 C.F.R. §1.322 to correct the errors in the patent as set forth hereinbelow and on the enclosed copy of Patent Office Form PTO-1050. Form PTO-1050 is attached hereto in duplicate with at least one copy being suitable for printing.

**IN THE CLAIMS:**

In Column 16, Line 53,

now reads "reducing cardiac dysfunctions ...", and  
should read --reducing cardiac dysfunction ...--

In Column 16, Line 55,

now reads "patholoaical excess of noreninephrine  
release, ....", and should read -- pathological  
excess of norepinephrine release,...--

In Column 16, Line 56,

now reads "comprising a administering...", and  
should read --comprising administering ....--

In Column 17, Line 1,

now reads "S- $\alpha$ -chloromethylhistamine ..." and  
should read --S- $\alpha$ -chloromethylhistamine ...--

In Column 17, Line 20,

now reads "The method according to claim 1,...",  
and should read --The method according to claim  
10, ...--

In Column 17, Line 23,

now reads "agonist inhibits the Na<sup>+</sup> H<sup>+</sup>...", and  
should read --agonist inhibits the Na<sup>+</sup>/H<sup>+</sup> ...--

In Column 17, Line 25,

now reads "agonist inhibits the Na<sup>+</sup> H<sup>+</sup>  
exchanger...", and should read -- agonist inhibits  
the Na<sup>+</sup>/H<sup>+</sup> exchanger ...--

In Column 17, Line 36,

now reads "N-type Ca<sup>2+</sup> channel.", and should read  
-- N-type Ca<sup>2+</sup> channel.--

In Column 18, Line 1,

now reads "inhibiting the Na<sup>+</sup> H<sup>+</sup> exchanger...",  
and should read -- inhibiting the Na<sup>+</sup>/H<sup>+</sup> exchanger  
...--

In Column 18, Line 4,

now reads "histamine H<sup>3</sup> receptor agonist.", and  
should read -- histamine H<sub>3</sub> receptor agonist.--

In Column 18, Line 13,

now reads "methylbistamine,...", and should read --  
methyhistamine, ...--

In Column 18, Line 41,


now reads "an anti-arrhythmic,...", and should read  
-- an anti-arrhythmic, ...--

The above-identified errors occurred through no fault of the Applicants. Accordingly, no  
fee is enclosed.

Application Serial No: 10/076,204  
Filing Date: February 13, 2002  
Docket No. 955-16  
Page 3 of 3

It is respectfully requested that a Certificate of Correction be issued to correct the errors in the above-identified patent.

Respectfully submitted,

  
Edna I. Gergel, Ph.D.  
Registration No. 50,819  
Agent for Applicants

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
Tel, 516-822-3550  
Fax. 516-822-3582  
EIG:jlw  
204708\_1

UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,884,809 B2  
DATED : May 13, 2005  
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

**IN THE CLAIMS:**

<u>In Column 16, Line 53,</u>	now reads "reducing cardiac dysfunctions ...", and should read --reducing cardiac dysfunction ...--
<u>In Column 16, Line 55,</u>	now reads "patholoaical excess of noreninephrine release, ....", and should read -- pathological excess of norepinephrine release,...--
<u>In Column 16, Line 56,</u>	now reads "comprising a administering...", and should read --comprising administering ....--
<u>In Column 17, Line 1,</u>	now reads "S- $\alpha$ -chloromethylhistarnine ..." and should read --S- $\alpha$ -chloromethylhistamine ...--
<u>In Column 17, Line 20,</u>	now reads "The method according to claim 1,...", and should read --The method according to claim 10, ...--
<u>In Column 17, Line 23,</u>	now reads "agonist inhibits the Na <sup>+</sup> H <sup>+</sup> ...", and should read --agonist inhibits the Na <sup>+</sup> /H <sup>+</sup> ...--
<u>In Column 17, Line 25,</u>	now reads "agonist inhibits the Na <sup>+</sup> H <sup>+</sup> exchanger...", and should read -- agonist inhibits the Na <sup>+</sup> /H <sup>+</sup> exchanger ...--

MAILING ADDRESS OF SENDER  
Edna I. Gergel, Ph.D.  
HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,884,809 B2  
DATED : May 13, 2005  
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

<u>In Column 17, Line 36,</u>	now reads "N-type Ca <sup>2+</sup> channel.", and should read -- N-type Ca <sup>2+</sup> channel.--
<u>In Column 18, Line 1,</u>	now reads "inhibiting the Na <sup>+</sup> H <sup>+</sup> exchanger...", and should read -- inhibiting the Na <sup>+</sup> /H <sup>+</sup> exchanger ...--
<u>In Column 18, Line 4,</u>	now reads "histamine H <sup>3</sup> receptor agonist.", and should read -- histamine H <sub>3</sub> receptor agonist.--
<u>In Column 18, Line 13,</u>	now reads "methylbistamine,...", and should read -- methylhistamine, ...--
<u>In Column 18, Line 41,</u>	now reads "an anti-arrhythmic,...", and should read -- an anti-arrhythmic, ...--

MAILING ADDRESS OF SENDER  
Edna I. Gergel, Ph.D.  
HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,884,809 B2  
DATED : May 13, 2005  
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

**IN THE CLAIMS:**

<u>In Column 16, Line 53,</u>	now reads "reducing cardiac dysfunctions ...", and should read --reducing cardiac dysfunction ...--
<u>In Column 16, Line 55,</u>	now reads "patholoaical excess of noreninephrine release, ...", and should read -- pathological excess of norepinephrine release,...--
<u>In Column 16, Line 56,</u>	now reads "comprising a administering...", and should read --comprising administering ...--
<u>In Column 17, Line 1,</u>	now reads "S- $\alpha$ -chloromethylhistarnine ..." and should read --S- $\alpha$ -chloromethylhistamine ...--
<u>In Column 17, Line 20,</u>	now reads "The method according to claim 1,...", and should read --The method according to claim 10, ...--
<u>In Column 17, Line 23,</u>	now reads "agonist inhibits the Na <sup>+</sup> H <sup>+</sup> ...", and should read --agonist inhibits the Na <sup>+</sup> /H <sup>+</sup> ...--
<u>In Column 17, Line 25,</u>	now reads "agonist inhibits the Na <sup>+</sup> H <sup>+</sup> exchanger...", and should read -- agonist inhibits the Na <sup>+</sup> /H <sup>+</sup> exchanger ...--

MAILING ADDRESS OF SENDER  
Edna I. Gergel, Ph.D.  
HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,884,809 B2  
DATED : May 13, 2005  
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

<u>In Column 17, Line 36,</u>	now reads "N-type Ca <sup>2+</sup> channel.", and should read -- N-type Ca <sup>2+</sup> channel.--
<u>In Column 18, Line 1,</u>	now reads "inhibiting the Na <sup>+</sup> H <sup>+</sup> exchanger...", and should read -- inhibiting the Na <sup>+</sup> /H <sup>+</sup> exchanger ...--
<u>In Column 18, Line 4,</u>	now reads "histamine H <sup>3</sup> receptor agonist.", and should read -- histamine H <sub>3</sub> receptor agonist.--
<u>In Column 18, Line 13,</u>	now reads "methylbistamine,...", and should read -- methylhistamine, ...--
<u>In Column 18, Line 41,</u>	now reads "an anti-arrhythmic,...", and should read -- an anti-arrhythmic, ...--

MAILING ADDRESS OF SENDER  
Edna I. Gergel, Ph.D.  
HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791

PATENT NO. 6,884,809 B2